Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy

Journal of Surgical Oncology

Volumn 98, Issue 4, 2008, Pages 247-252

  Kusamura, Shigeki ^a   Dominique, Elias ^b   Baratti, Dario ^a   Younan, Rami ^c   Deraco, Marcello ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Consensus; Hyperthermic intraperitoneal chemotherapy; Peritoneal carcinomatosis

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUCOSE; HYPOTONIC SOLUTION; IRINOTECAN; ISOTONIC SOLUTION; MELPHALAN; MITOMYCIN C; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CELL CYCLE; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; DELPHI STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG PENETRATION; HUMAN; HYPERTHERMIA; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MAXIMUM TOLERATED DOSE; MOLECULAR WEIGHT; PRIORITY JOURNAL; TEMPERATURE; TEMPERATURE MEASUREMENT;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG CARRIERS; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; PERITONEAL NEOPLASMS;

EID: 50849102716     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21051     Document Type: Conference Paper

References (54)

1. Elias D, Bonnay M, Puizillou JM, et al.: Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002;13:267-272.
2. Sugarbaker PH, Stuart OA, Carmignani CP: Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 2006;57:703-708.
3. Smeenk RM, Verwaal VJ, Zoetmulder FA: Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei - A report of 103 procedures. Eur J Surg Oncol 2006;32:186-190. Epub November 21, 2005.
4. Shido A, Ohmura S, Yamamoto K, et al.: Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion? World J Surg 2000;24:507-511.
5. Moran BJ, Mukherjee A, Sexton R: Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 2006;93:100-104.
6. Glehen O, Cotte E, Brigand C, et al.: Therapeutic innovations in the management of peritoneal carcinomatosis from digestive origin: Cytoreductive surgery and intraperitoneal chemotherapy [Article in French]. Rev Med Int 2006;27:382-391. Epub October 5, 2005.
7. Elias D, Raynard B, Boige V, et al.: Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 2005;90:220-225.
8. Christophi C, Winkworth A, Muralihdaran V, et al.: The treatment of malignancy by hyperthermia. Surg Oncol 1998;7:83-90. Review.
9. Shimizu T, Maeta M, Koga S: Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat. Br J Surg 1991;78:57-59.
10. Loughlin KG, Moore LF: Using Delphi to achieve congruent objectives and activities in a pediatrics department. J Med Educ 1979;54:101-106.
11. Keeney S, Hasson F, McKenna H: Consulting the oracle: Ten lessons rom using the Delphi technique in nursing research. J Adv Nurs 2006;53:205-212.
12. Sugarbaker PH: Early postoperative intraperitoneal adriamycin as an adjuvant treatment for advanced gastric cancer with lymph node or serosal invasion. In: Sugarbaker PH, editor. Management of Gastric Cancer. Boston: Kluwer; 1991: pp. 277-284.
13. Sugarbaker PH, Mora JT, Carmignani P, et al.: Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005;10:112-122.
14. Glehen O, Stuart OA, Mohamed F, et al.: Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model. Cancer Chemother Pharmacol 2004;54:79-84.
15. Washington Cancer Institute Protocol #X02380.
16. van Ruth S, Verwaal VJ, Zoetmulder FAN: Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 2003;12:771-780.
17. Gonzalez-Moreno S: Peritoneal surface oncology: A progress report. Eur J Surg Oncol 2006; [Epub ahead of print].
18. Zoetmulder FA, van der Vange N, Witkamp AJ, et al.: Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma: Good preliminary results from the Netherlands Cancer Institute [Article in Dutch]. Ned Tijdschr Geneeskd 1999;143:1863-1868.
19. Park BJ, Alexander HR, Libutti SK, et al.: Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999;6:582-590.
20. Zeamari S, Floot B, van der Vange N, et al.: Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). Anticancer Res 2003;23:1643-1648.
21. Van Bree C, Beumer C, Rodermond HM, et al.: Effectiveness of 2′,2′difluorodeoxycytidine (Gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia 1999;15:549-556.
22. Sabbatini P, Aghajanian C, Leitao M, et al.: Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: Results of a phase I/II trial. Clin Cancer Res 2004;10: 2962-2967.
23. Oza AM, ten Bokkel Huinink W, Dubbelman R, et al.: Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. Ann Oncol 1994;5:343-347.
24. Link KH, Roitman M, Holtappels M, et al.: Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am 2003;12:865-872.
25. Nicoletto MO, Padrini R, Galeotti F, et al.: Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol 2000;45:457-462.
26. Elias D, Sideris L, Pocard M, et al.: Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncol 2004;15:781-785.
27. O'Dwyer PJ, LaCreta FP, Daugherty JP, et al.: Phase I pharmacokinetic study of intraperitoneal etoposide. Cancer Res 1991;51:2041-2046.
28. Yonemura Y, Fujimura T, Nishimura G, et al.: Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437-444.
29. Yonemura Y, Bandou E, Kinoshita K, et al.: Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am 2003;12:635-648. Review.
30. Mohamed F, Sugarbaker PH: Intraperitoneal taxanes. Surg Oncol Clin N Am 2003;12:825-833.
31. Morgan RJ Jr, Doroshow JH, Synold T, et al.: Phase I trial of intraperitoneal docetaxel in the treatment of advancedmalignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 2003;9:5896-5901.
32. de Bree E, Romanos J, Michalakis J, et al.: Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 2003;23:3019-3027.
33. Speyer JL, Collins JM, Dedrick RL, et al.: Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 1980;40:567-572.
34. Maeta M, Sawata T, Kaibara N: Effects of hyperthermia on the metabolism of 5-fluorouracil in vitro. Int J Hyperthermia 1993;9:105-113.
35. Tsumura M, Yoshiga K, Takada K: Enhancement of antitumor effects of 1-hexylcarbamoyl-5-fluorouracil combined with hyperthermia on Ehrlich ascites tumor in vivo and Nakahara-Fukuoka sarcoma cell in vitro. Cancer Res 1988;48:3977-3980.
36. Steller MA, Egorin MJ, Trimble EL, et al.: A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999;43:106-114.
37. Malmstrom H, Larsson D, Simonsen E: Phase I study of intraperitoneal carboplatin as adjuvant therapy in early ovarian cancer. Gynecol Oncol 1990;39:289-294.
38. Speyer JL, Beller U, Colombo N, et al.: Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol 1990;8:1335-1341.
39. Rossi CR, Foletto M, Mocellin S, et al.: Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: Phase I study. Cancer 2002;94:492-499.
40. Deraco M, De Simone M, Rossi CR, et al.: An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res 2003;22:41-45.
41. Deraco M, Casali P, Inglese MG, et al.: Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003;83:147-153.
42. Rossi CR, Deraco M, De Simone M, et al.: Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: Clinical outcome and prognostic factors in 60 consecutive patients. Cancer 2004;100:1943-1950.
43. Raspagliesi F, Kusamura S, Campos Torres JC, et al.: Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol 2006.
44. Pilati P, Mocellin S, Rossi CR, et al.: Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003;10:508-513.
45. Deraco M, Baratti D, Inglese MG, et al.: Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): A strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004;11:393-398.
46. Ryu KS, Kim JH, Ko HS, et al.: Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 2004;94:325-332.
47. Torres IJ, Litterst CL, Guarino AM: Transport of model compounds across the peritoneal membrane in the rat. Pharmacology 1978;17:330-340.
48. Groose E, Walker L, Masters JR: The influence of osmolarity on drug cytotoxicity in vitro. Br J Cancer 1986;54:181.
49. Kondo A, Maeta M, Oka A, et al.: Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br J Cancer 1996;73:1166-1170.
50. Tsujitani S, Oka A, Kondo A, et al.: Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats. Oncology 1999;57:77-82.
51. Elias D, El Otmany A, Bonnay M, et al.: Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 2002;63:346-352.
52. Pestieau SR, Schnake KJ, Stuart OA, et al.: Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol 2001;47:269-276.
53. Litterst CL, Torres IJ, Arnold S, et al.: Adsorption of antineoplastic drugs following large-volume ip administration torats. Cancer Treat Rep 1982;66:147-155.
54. McArdle CS, Kerr DJ, O'Gorman P, et al.: Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: A long-term intraperitoneal treatment approach for advanced colorectal carcinoma. Br J Cancer 1994;70:762-766.